Neuromuscular · Clinical trials
Duchenne Muscular Dystrophy Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About duchenne muscular dystrophy — and why its trials are hard
Duchenne muscular dystrophy (DMD) is a severe, X-linked recessive disorder caused by mutations in the DMD gene that abolish functional dystrophin, a protein essential for muscle-fibre membrane stability. It affects mainly boys, causing progressive muscle degeneration with loss of ambulation typically in the early teens, followed by respiratory and cardiac failure. Corticosteroids (prednisone/prednisolone, deflazacort, and the modified steroid vamorolone) remain the foundational therapy, prolonging ambulation and preserving muscle strength. A class of exon-skipping antisense oligonucleotides—eteplirsen, golodirsen, viltolarsen, and casimersen—received accelerated FDA approval for specific amenable mutations based on the surrogate endpoint of increased dystrophin production; the small and uncertain clinical magnitude of this dystrophin surrogate has made these approvals scientifically contested. Givinostat, a histone deacetylase inhibitor, was approved in 2024 to slow functional decline. In 2023, delandistrogene moxeparvovec (Elevidys), an AAV-delivered micro-dystrophin gene therapy, received accelerated approval—also controversial after its confirmatory EMBARK trial missed its primary functional endpoint despite supportive secondary data. Endpoints span dystrophin quantification, timed function tests, the North Star Ambulatory Assessment (NSAA), and pulmonary measures.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Corticosteroids (prednisone/deflazacort; vamorolone) (Emflaza (deflazacort); Agamree (vamorolone)) | 2017 (deflazacort); 2023 (vamorolone) | Foundational therapy across DMD regardless of mutation | Multiple RCTs; VISION-DMD (vamorolone) | Muscle strength/function (e.g., time to stand); NSAA | Steroids delay loss of ambulation by years; vamorolone showed efficacy with a more favourable bone/growth safety profile |
| Eteplirsen (exon 51 skipping) (Exondys 51) | 2016 | DMD with mutations amenable to exon 51 skipping (~13% of patients) | Study 201/202 (small) | Dystrophin production (surrogate) under accelerated approval | Small increase in dystrophin (single-digit % of normal); clinical benefit not established—surrogate-endpoint approval widely contested |
| Golodirsen / Viltolarsen (exon 53); Casimersen (exon 45) (Vyondys 53 / Viltepso; Amondys 45) | 2019 / 2020; 2021 | DMD amenable to exon 53 or exon 45 skipping | Phase I/II dystrophin studies | Dystrophin production (surrogate) under accelerated approval | Modest dystrophin increases; functional benefit unconfirmed—same surrogate-endpoint controversy |
| Givinostat (Duvyzat) | 2024 | DMD in patients >=6 years (all mutations); oral HDAC inhibitor | EPIDYS (phase 3) | Change in four-stair-climb time (function) | Slowed decline in four-stair-climb versus placebo over 18 months |
| Delandistrogene moxeparvovec (Elevidys) | 2023 | DMD (initially ambulatory 4-5 yrs; expanded 2024); one-time AAV micro-dystrophin gene therapy | EMBARK (confirmatory phase 3); Study 101/103 | Micro-dystrophin expression (accelerated approval); NSAA change (confirmatory) | Robust micro-dystrophin expression but EMBARK missed its primary NSAA endpoint at 52 weeks; secondary timed-function measures favoured treatment—full/expanded approval remained contested |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in duchenne muscular dystrophy development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Exon-skipping dystrophin surrogate endpoint (class-level) — Eteplirsen and successors' accelerated-approval basis | Approvals rested on small increases in dystrophin whose translation to clinical benefit remains unproven; FDA reviewers and outside scientists publicly disputed the evidence | Very small dystrophin quantities, tiny/uncontrolled trials, and unvalidated surrogate; confirmatory clinical benefit still outstanding |
| Ataluren (readthrough of nonsense mutations) — ACT DMD (phase 3) | Failed to meet its primary 6-minute-walk-distance endpoint; not FDA-approved (conditional approval in EU later withdrawn as unconfirmed) | No confirmed functional benefit; EU marketing authorisation ultimately not renewed |
| Drisapersen (exon 51 skipping, 2'-O-methyl backbone) — Phase 3 | Missed primary endpoint and FDA rejected it in 2016 over efficacy and safety (renal, injection-site) concerns | Lack of demonstrated efficacy and toxicity signals |
Choosing the right endpoint
Primary endpoints that matter in duchenne muscular dystrophy trials
- Dystrophin (or micro-dystrophin) expression — Surrogate endpoint underpinning accelerated approvals of exon-skippers and Elevidys; clinical correlation contested
- North Star Ambulatory Assessment (NSAA) — Composite ambulatory function scale; primary confirmatory endpoint in EMBARK
- Timed function tests (four-stair climb, 10-metre run/walk, rise from floor) — Sensitive functional measures; four-stair climb was the EPIDYS givinostat endpoint
- 6-minute walk distance (6MWD) — Classic ambulatory endpoint; primary endpoint that ataluren failed in ACT DMD
- Pulmonary function (FVC) and time to loss of ambulation — Long-term disease-progression outcomes reflecting respiratory decline and mobility
How iNGENū runs duchenne muscular dystrophy trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Duchenne Muscular Dystrophy clinical trials — FAQs
Why are the exon-skipping drugs for DMD controversial?
Did the Elevidys gene therapy prove it works?
What is the foundational treatment for DMD?
Ready to discuss your duchenne muscular dystrophy trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal